Cart
sales@molnova.com
Tris(2,2,2-trifluoroethyl) borate
CAS No. 659-18-7
Tris(2,2,2-trifluoroethyl) borate( —— )
Catalog No. M15508 CAS No. 659-18-7
Tris(2,2,2-trifluoroethyl) borate is mostly used in condensation reactions.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 44 | In Stock |
|
| 50MG | 75 | In Stock |
|
| 100MG | 128 | In Stock |
|
| 200MG | 194 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTris(2,2,2-trifluoroethyl) borate
-
NoteResearch use only, not for human use.
-
Brief DescriptionTris(2,2,2-trifluoroethyl) borate is mostly used in condensation reactions.
-
DescriptionTris(2,2,2-trifluoroethyl) borate is mostly used in condensation reactions. It has been shown to promote the direct formation of amides from carboxylic acids and amines as well as the formation of imines from amines or amides with carbonyl compounds.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number659-18-7
-
Formula Weight307.91
-
Molecular FormulaC6H6BF9O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: > 11 mM
-
SMILESFC(F)(F)COB(OCC(F)(F)F)OCC(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Rait JL. Aust N Z J Ophthalmol. 1999, 27(1):57-64.
molnova catalog
related products
-
3-Methylhistamine di...
N tau-methylhistamine is one of the histamine metabolites. N tau-methylhistamine in plasma and urine is a good parameter for histamine release and the determination of this histamine metabolite is generally less hampered by possible artifacts (due to basophil disrupture a very short half-life time or bacterial production) than determinations of histamine itself.
-
TNCA
TNCA is a high-affinity CaSR ligand (CaSRL) with co-agonist activity.
-
MC-Val-Ala-PAB-PNP
MC-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
